Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET
Company Participants
Erin Graves – Senior Director of Corporate Communications and Investor Relations
Mark Goldsmith – Chairman and Chief Executive Officer
Jack Anders – Chief Financial Officer
Steve Kelsey – President of Research & Development
Conference Call Participants
Marc Frahm – TD Cowen
Faisal Khushid – Leerink Partners
Jay Olson – Oppenheimer
Ami Fadia – Needham
Alec Stranahan – Bank of America
Ben Burnett – Stifel
Operator
Good day and thank you for standing by. Welcome to Revolution Medicine's Second Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Erin Graves, Senior Director of Corporate Communications and Investor Relations. Please go ahead.
Erin Graves
Thank you and welcome, everyone, to the second quarter 2023 earnings call. Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicine's Chairman and Chief Executive Officer; and Jack Anders, our Chief Financial Officer. Dr. Steve Kelsey, our President of R&D, will join us for the Q&A portion of today's call. As we begin, I would like to note that our presentation will include statements regarding the current beliefs of Revolution Medicines with respect to our business and the proposed acquisition of EQRx including statements regarding our development plans and timelines for our portfolio and pipeline and the expected timing and benefits of the proposed acquisitions, all of which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements.
These statements are subject to a number of assumptions, risks and uncertainties. Actual results may differ materially from these statements and except as required by law, the company undertakes no obligation to revise or update any forward-looking statements. I encourage you to review the legal disclaimer slide of our corporate presentation or earnings press release and all of our filings with the SEC concerning these and other matters. In connection with the proposed EQRx acquisition, Revolution Medicines and EQRx intend to file documents with the SEC including a registration statement on Form S-4 containing a joint proxy statement and perspectives. Investors and security holders are urged to read carefully the joint proxy statement and prospectus when it is filed with the SEC and other documents filed by either Revolution Medicines or EQRx with the SEC relating to the proposed transaction when they are filed because they will contain important information.